Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes

Sponsor
Hvidovre University Hospital
Study ID
NCT00993720
Phase
PHASE2/PHASE3
Status
Completed

Conditions

  • Diabetes Mellitus

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
  • Liraglutide — DRUG
    after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
  • continuous insulin therapy — OTHER
    after optimal treatment with insulin, patients continue on insulin for four weeks

Study Details

The aim of the study is to investigate the effect of Victoza (a GLP-1 receptor agonist)on insulin-dose, risk of hypoglycemia and gastric emptying rate during hypoglycemia in patients with type 1 diabetes.

Key Dates

Start date
Oct 31, 2009
Status verified
Oct 2009
Primary completion
Oct 31, 2010
Completion
Oct 31, 2010

Study Design

Enrollment
30 participants (actual)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: type 1 DM with betacell function: Liraglutide
  • Experimental: type 1 DM without betacell function: Liraglutide
  • No Intervention: type 1 DM without betacell function: Insulin

Primary Outcome Measure

insulin-dose [ Time Frame: 4 weeks ]

Related Studies